107
Participants
Start Date
May 5, 2021
Primary Completion Date
October 20, 2022
Study Completion Date
October 20, 2022
TAVT-45
250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
Zytiga
500 mg tablet, two tablets administered once daily
Prednisone
mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
Research Site, Budapest
Research Site, Budapest
Research Site, Debrecen
Research Site, New York
Research Site, Annapolis
Research Site, Virginia Beach
Research Site, Lleida
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Brest
Research Site, Bradenton
Research Site, Homewood
Research Site, Seville
Research Site, Jeffersonville
Research Site, Troy
Research Site, Little Rock
Research Site, Denver
Research Site, Meridian
Research Site, Tucson
Research Site, Los Angeles
Research Site, Suresnes
Research Site, San Bernardino
Research Site, Warsaw
Research Site, Bydgoszcz
Research Site, Lublin
Research Site, Piaseczno
Research Site, Warsaw
Research Site, Ponce
Research Site, Manresa
Research Site, Barcelona
Research Site, Barcelona
Research Site, Barcelona
Research Site, Gothenburg
Research Site, Västerås
Research Site, Torquay
Research Site, Cheltenham
Research Site, Hampstead
Research Site, Glasgow
Research Site, Guildford
Research Site, London
Lead Sponsor
Tavanta Therapeutics
INDUSTRY